Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Keywords

MedicineTrastuzumabChillsBreast cancerMetastatic breast cancerInternal medicineDiscontinuationAdverse effectCancerHazard ratioNauseaGastroenterologySurgeryOncologyConfidence interval

Affiliated Institutions

Related Publications

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

Manfred Hofmann , Oliver Stoß , Di Shi +6 more

Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring ...

2008 Histopathology 1169 citations

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein , Lyndsay N. Harris , P. Kelly Marcom +15 more

Purpose: Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. We conducted a multicenter p...

2003 Journal of Clinical Oncology 343 citations

Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett , Marion Procter , Worta McCaskill‐Stevens +11 more

Purpose To determine whether (1) immunohistochemical (IHC) HER2 status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) HE...

2009 Journal of Clinical Oncology 184 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh , Charles L. Vogel , Debu Tripathy +8 more

PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recom...

1999 Journal of Clinical Oncology 2778 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

José Baselga , Debu Tripathy , John Mendelsohn +11 more

PURPOSE Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody ...

1996 Journal of Clinical Oncology 1400 citations

Publication Info

Year: 2002
Type: article
Volume: 20
Issue: 3
Pages: 719-726
Citations: 2948
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2948

OpenAlex

Cite This

APA Style

                            
                                
                                    Charles L. Vogel, 
                                
                                    Melody Cobleigh, 
                                
                                    Debu Tripathy
                                
                                et al.
                            
                            (2002). 
                            Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. 
                            Journal of Clinical Oncology
                            , 20
                            (3)
                            , 719-726.
                            https://doi.org/10.1200/jco.20.3.719
                        

Identifiers

DOI: 10.1200/jco.20.3.719